Back

Impact of sodium-glucose cotransporter-2 (SLGT2) inhibitors treatment initiation on the reduction of atrial and ventricular arrhythmias in patients with implanted cardiac devices.

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Update on EP studies, anti-arrhythmic drugs, and ablation techniques Antiarrhythmic Drug Treatment ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Enrique Sanchez Munoz

Hospital of Leon, Leon (Spain)

5 More presentations in this session

Presentation thumbnail
High-power short-duration ablation of the atrioventricular node
Doctor M. Alsaiqali (Sioux Falls, US)
Abstract Slides Video
Presentation thumbnail
Risk of stiff left atrial syndrome following pulse-field-based ablation of atrial fibrillation in patients with pulmonary hypertension at baseline
Doctor S. Mohanty (Austin, US)
Abstract Slides Video
Presentation thumbnail
A comparison of general anesthesia versus monitored anesthesia care during catheter ablation for ventricular tachycardia
Ms T. Woelber (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Atypical flutter: effectiveness of a systematic strategy based on comprehensive high-density map analysis
Doctor J. Brito (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Risk of complications in patients undergoing pulmonary vein antrum isolation: a single centre experience
Doctor M. Pirbaglou (Newmarket, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Update on EP studies, anti-arrhythmic drugs, and ablation techniques

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources